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Background: Chronic obstructive pulmonary disease and lung can-
cer are linked because both airflow obstruction and emphysema, on 
computer tomography, are independent risk factors for lung cancer. 
However, the local risk of malignancy relative to development of 
regional emphysema has not yet been defined. Specifically, it is not 
known if primary lung cancers are associated with regions of worse 
emphysema within individual patients.
Methods: We performed a database analysis evaluating the associa-
tion between the degree of regional emphysema as scored on com-
puter tomography and development of primary lung cancer. We also 
studied the association between regional emphysema and benign lung 
nodules. We assembled two distinct cohorts using the National Heart, 
Lung, and Blood Institute’s Lung Tissue Research Consortium data-
base, hypothesizing that lung malignancy will preferentially locate in 
the regions of the most severe emphysema.
Results: In the Lung Tissue Research Consortium database, 624 
cases met criteria for the malignant nodule cohort and 64 were 
included in the benign nodule cohort. When comparing location of a 
malignant nodule to other lung regions within the same person, the 
odds of having a more severe emphysema score in the location of 
lung cancer was 1.342 (95% confidence interval 1.112–1.620; p = 
0.0022). When comparing location of a benign nodule to other lung 
regions within the same person, the odds of having a more severe 
emphysema score in the location of the benign nodule was 1.118 
(95% confidence interval 0.725–1.725; p = 0.6137).
Conclusions: Primary lung cancers are associated with areas of 
worse regional emphysema.
Key Words: Emphysema, COPD, Lung cancer, Computerized 
tomography.
(J Thorac Oncol. 2014;9: 639–645)
Lung cancer is the leading cause of cancer death in the United States, and the overall 5-year survival rate remains a dismal 
16%.1 Despite an overwhelming need for better detection and 
treatment of lung cancer, an effective screening method has 
remained elusive. Recently, computer tomography (CT) has 
shown promise as an effective means of screening for cancer. 
The National Lung Cancer Screening Trial demonstrated a 
20% reduction in mortality of a high-risk population in those 
that received screening by low-dose CT.2 However, this method 
was found to be fraught with an unacceptably high level of 
false-positive findings (95%), resulting in a very high bur-
den of cost and exposure to imaging and procedures for those 
with benign disease. Nonetheless, the National Lung Cancer 
Screening Trial serves as a strong reminder of the need to bet-
ter understand the risk factors for the development of lung can-
cer, so that individuals at risk can be more precisely stratified.
Chronic obstructive pulmonary disease (COPD) is one 
of the most well-established risk factors for the development of 
lung cancer. COPD itself accounts for approximately one in 20 
deaths in the United States, and its mortality rate has continued 
to rise over the past decade.3 Tobacco use was long believed to 
be the only link between the two diseases. However, since the 
1980s, studies have shown COPD itself to be an independent 
risk factor for lung cancer.4,5 This data showed a connection 
between air flow obstruction, as measured by pulmonary func-
tion tests (% predicted forced expiratory volume in 1 second), 
and the risk of lung cancer. These first studies showed that, 
even when tobacco exposure was accounted for, those with air-
way obstruction were up to four times more likely to develop 
and die of lung cancer.4,5 Subsequently, we have also learned 
that this relationship is severity dependent, indicating that as 
airway obstruction worsens, the risk of lung cancer increases.5
The relationship between airflow obstruction and lung 
cancer has been well defined, but the clinical entity of COPD 
encompasses more than simply airflow obstruction. COPD 
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includes a spectrum of clinical phenotypes. These phenotypes 
are characterized by varying degrees of airflow limitation, 
chronic bronchitis, and emphysema. Until recently, the rela-
tionship between emphysema and lung cancer was unclear. 
However, with the technological advancement of imaging 
techniques, CT has become the standard procedure for non-
invasively diagnosing and quantifying emphysema.6 Recent 
studies, using semiquantitative emphysema scores based on 
visual assessment of CTs, have shown that the presence of 
emphysema is an independent risk factor for lung cancer.7–9 
These large population-based studies have shown that indi-
viduals with visible emphysema on CT were approximately 
three times as likely to develop lung cancer than those without 
emphysema. This relationship held true even in the absence of 
airflow obstruction.
These recent CT studies have explored the presence 
of emphysema related to overall risk of malignancy, but did 
not evaluate the relationship of the presence or magnitude 
of regional emphysematous changes to the location of the 
lung cancer. In fact, emphysema is a heterogeneous process 
throughout the lungs, with some regions, often the apices, 
being affected more than others. In addition, it is a chronic, 
inflammatory process characterized by up-regulation of vari-
ous cytokines, including tumor necrosis factor-α, interleu-
kin (IL)-1β, and IL-6. This may engender a pro-oncogenic 
milieu.10 However, it remains unknown whether lung cancers 
are more likely to be found in areas of the lung with worse 
emphysema within the same person. We hypothesized that pri-
mary lung cancers will be preferentially associated with the 
areas of the lung with the greatest amount of regional emphy-
sema. In addition, we hypothesized that benign lung nodules 
would not preferentially be localized to areas of the lung with 
the greatest degrees of regional emphysema.
To test these hypotheses, we conducted a database 
review using the National Heart, Lung, and Blood Institute 
(NHLBI) Lung Tissue Research consortium (LTRC) data-
base.11 From the available cases, we sought to correlate the 
location of both primary lung cancers and benign lung nod-
ules with CT regional emphysema scores (RES).
MATERIALS AND METHODS
Participants
Participants for this study were identified in the NHLBI 
LTRC database.11 This database’s primary goal was to col-
lect lung tissue and blood from patients who were referred 
for lung resection. Patients enrolled included (1) individuals 
with COPD scheduled to have lung volume reduction sur-
gery, lung transplant, or resection of suspected malignancy, 
(2) patients with interstitial lung disease scheduled to undergo 
video-assisted thorascopic surgery or lung transplant, and 
(3) control subject without a primary diagnosis of COPD or 
interstitial lung disease scheduled for resection of suspected 
malignancy. A secondary goal of the LTRC database was to 
collect clinical, physiological, and CT scan data. From this 
group, 1215 patients were available for review for the current 
study. Selection of cases of lung malignancy and benign nod-
ules was determined based on the “final clinical diagnosis” 
for each patient as assigned by the site investigator, 2 months 
after surgery. “Final clinical diagnosis” for the LTRC study 
was made using histopathologic diagnosis from resected lung 
specimens, in addition to supplemental radiographic and clini-
cal data. Primary lung cancers included non–small-cell lung 
cancer or small-cell lung cancer. Resected metastatic lesions 
and lymphoma were not included. This project has received 
approval from the Mayo Clinic IRB (IRB number 1640-04) 
last reviewed on February 5, 2013. Informed consent for this 
study was covered under the initial enrollment into the LTRC 
database.
CT Analysis
All CT images were obtained according to the proce-
dures outlined in the LTRC protocol. These studies included 
a variety of acquisition techniques depending on whether 
the images were obtained for clinical purposes before LTRC 
enrollment or whether the studies were obtained prospectively 
according to the high-resolution CT techniques specifically 
designed by the LTRC radiology core laboratory.12 All pro-
spective scans using the LTRC protocol were obtained using 
either General Electric or Siemens scanners with 16 or more 
detectors, and imaging parameters were standardized as much 
as possible among the enrollment centers (with slice thick-
ness 1.25 mm or less with 50% overlapping reconstruction in 
a high-spatial, frequency-preserving algorithm). For viewing 
and analysis of both retrospective clinical scans and LTRC 
protocol scans, the acquisition with the thinnest slice recon-
struction obtained during supine inspiration was used for eval-
uation of emphysema and other parenchymal abnormalities.
Regional emphysema was scored in a semiquantitative 
fashion by an experienced thoracic radiologist as part of the 
LTRC radiology core laboratory evaluation of the images 
according to a scale modified from the National Emphysema 
Treatment Trial guidelines.13 Emphysema involvement 
was classified as follows: 0, none; 1, mild = 1 to 25%; 2, 
moderate = 26 to 50%; 3, marked = 51 to 75%; and 4, severe 
greater than 75%. A regional emphysema score was given 
to each of 12 lung zones: right and left lungs; upper, mid-
dle (or lingua), lower lobes; and central versus peripheral 
regions based on a distance less or more than 5 cm from the 
hilar structures. The interpreting radiologist was blinded 
to all clinical data except for patient age. Specifically, the 
presumed preoperative diagnosis, the smoking status, pres-
ence or absence of malignancy on pathological specimens, 
and all physiologic data were unknown at the time of visual 
regional emphysema estimation. Benign and malignant nod-
ule location was not available in the LTRC database but was 
confirmed by visual review of the CT scan data and avail-
able surgical site data based on a final clinical diagnosis of 
primary lung cancer; 624 CT scans were again reviewed 
using OsiriX Imaging Software DICOM Viewer (version 
5.6, http://www.osirix-viewer.com) on a 5-megapixel LCD 
display. Location of the nodule was documented as being in 
one of 12 lung regions as described previously with regional 
emphysema scoring. The same process was carried out on 64 
CT scans of those with a final clinical diagnosis consistent 
with benign nodules. The nodule location was determined by 
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the first author with review by B.J.B., an experienced chest 
radiologist and principal radiologist of the NHLBI LTRC 
database. At the time of visual review for nodule localiza-
tion, both were unblinded to the characteristic of the nodule 
(malignant versus benign) because of the structure of the 
study. This visual review primarily served to confirm nod-
ule location already registered with the pathology specimens 
found within the LTRC database.
Pulmonary Function Testing
Spirometric data were obtained using standards set 
forth by American Thoracic Society (ATS) recommen-
dations for accuracy and precision.14,15 Reference equa-
tions by Hankinson et al.16 were used. Diffusion capacities 
were obtained using standard techniques according to ATS 
recommendations.17 Reference equations by Crapo and 
Morris18 were used. Diffusing capacity for carbon monoxide 
(DLCO) measurements were corrected for hemoglobin as 
available in the LTRC database; however, both corrected and 
uncorrected measurements were reported. Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) stages 
were assigned as described in the 2007 Global Executive 
Summary.19
Statistical Analysis
Baseline characteristics were summarized with contin-
uous variables being reported as means and standard devia-
tions or medians and interquartile ranges (if not normally 
distributed). Categorical values were reported as counts and 
frequencies. Conditional logistic regression analysis was 
used on both the malignant (n = 624) and benign (n = 64) 
cohorts of participants to assess whether a higher regional 
emphysema score was a predictor of the presence of either 
a malignant or benign lung nodule. These parameters were 
stratified for each individual, using each subject in the LTRC 
database as one case (one lung region with nodule) and 11 
comparator control regions (i.e., 11 lung regions without 
nodule) for that given individual.
RESULTS
We had postulated that primary lung malignancies 
would be more likely to be associated with anatomic areas of 
worst radiographic emphysema, whereas benign lung nodules 
would not. To address this question, two cohorts of subjects 
were identified within the NHLBI LTRC database. The first 
was a cohort of patients with primary lung malignancies. As 
show in Figure 1, 624 patients were initially selected based 
FIGURE 1.  Selection of patient 
records into malignant and benign 
nodule cohorts.
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on a “final clinical diagnosis” of lung cancer, presence of 
adequate CT images for review, and presence of a solitary 
nodule. Final analysis was conducted on 615 of these. Of the 
624 initial cases, in one case we were unable to localize the 
tumor by CT because of small size and incidental removal 
during lung surgery for other indications. Of the 623 remain-
ing cases, eight lacked reliable emphysema scores around the 
tumor usually because of architectural distortion of the lung, 
and thus they were also excluded, leaving a total of 615 cases 
for analysis. The second cohort was a cohort of subjects with 
benign lung nodules. Again, as shown in Figure 1, 64 subjects 
were selected based on a clinical diagnosis of a nodule that 
was proven to be benign.
The baseline characteristics of the patients in each cohort 
were analyzed and are summarized in Table 1. The malignant lung 
nodule cohort was evenly split between genders (men, 50.8%; 
women, 49.2%). The mean age was 67.1 ± 9.93 years, and the 
mean pack-year tobacco smoking history was 47.9 ± 32.5 years 
(one pack-year is defined as smoking one package of cigarettes 
per day for 1 year, whereas smoking one package per day for 
day years equates to 10 pack-years). The most frequent GOLD 
stage was 0 (40.8%). Among the type of primary cancers, 98% 
(n = 613) were non–small-cell lung cancer (NSCLC) with the 
rest being small cell. Further characterization into adenocarci-
noma or squamous cell was not available in the LTRC database. 
The benign cohort was also equally split between genders (men, 
50%; women, 50%). The average age was 61.4 years and mean 
pack-year tobacco smoking history was 53.9 ± 31.5 years. Most 
frequent GOLD stage was four (51.6%). Granulomatous disease 
was the most common etiology of the benign nodules represent-
ing 85% of these cases (n = 52).
The distribution of the emphysema severity dif-
fered between the two cohorts. Figure 2A, B describes the 
distribution of emphysema severity between the case regions 
(anatomic regions with a malignant nodule) compared with all 
control regions (lung regions without a nodule) in the malig-
nant nodule cohort. For both cases and controls, the most 
frequent regional emphysema score was 0 (no visible emphy-
sema; 52.7% and 60% in the two cohorts, respectively). There 
was a trend toward the case regions (those regions with a nod-
ule) having a higher emphysema score. Specifically, across 
all degrees of emphysema (1 through 4), there was a greater 
percentage in the case group compared with the control group.
Figure 3A, B shows the distribution of emphysema 
severity in the benign nodule cohort. The distribution of the 
severity of emphysema is more even across both case (con-
taining nodules) and control regions (not containing nodules) 
of the lung. The most frequent regional emphysema scores 
for both case and control regions were 0 (29.7% and 30.5%, 
respectively). The most severe degree of emphysema (4) was 
more frequently noted in the case regions (26.6% versus 
14.8%), but all other degrees of less severe emphysema were 
more often found in the control regions.
The above distributions do not take into account that 
our study had been stratified for each individual subject. 
Therefore, conditional logistic regression was next used to 
analyze the location of either malignant or benign lung nodule 
with respect to severity of regional emphysema, as quantified 
by a regional emphysema scores, within individual subjects. 
A higher regional emphysema score was associated with the 
presence of a malignant lung nodule [OR 1.342, 95% con-
fidence interval (CI) 1.112–1.620, p = 0.0022], as shown in 
Table 2. A malignant nodule was also more likely to be found 
on the right side (versus left, p < 0.001), in the upper lobe (ver-
sus middle or lower, p = 0.0093), and in the peripheral region 
of the lobe (versus central, p < 0.001). This is consistent with 
a previously described series of non–small-cell carcinomas.20 
The most common location of a malignant nodule was found 
to be in the right upper peripheral region (27%).
In contrast, when analyzing the benign nodule cohort, 
a higher regional emphysema score was not associated with 
the presence of a benign lung nodule (OR 1.118, 95% CI 
0.725–1.725, p = 0.614), as shown in Table 3. A benign nod-
ule was less likely to be found in the middle lobe (p = 0.006). 
Benign nodules were also more likely to be found in the 
peripheral region of the lobe when compared with the central 
(p < 0.001), but otherwise did not show preference for lateral-
ity (R versus L) or upper lobe versus lower lobe location.
DISCUSSION
In this LTRC database review, we found that higher 
regional emphysema scores were associated with the presence 
of a primary lung cancer, but not a benign pulmonary nod-
ule. Our study was setup in such a way in that each subject 
acted as his/her own internal control, using regional analysis 
criteria to differentiate between the region with a nodule and 
those regions without. This provided us the unique opportunity 
to control for all known and unknown confounders, including 
age, gender, and cigarette exposure. Interestingly, we found 
that the degree of regional emphysema, and GOLD class, in 
the benign nodule cohort was of greater severity than in the 
TABLE 1.  Patient Demographics
Malignant Nodule Cohort 
(n = 624)
Benign Nodule 
Cohort (n = 64)
Sex, No (%)
  Male 317 (50.8) 32 (50)
  Female 307 (49.2) 32 (50)
Age, yr
  Mean (SD) 67.1 (9.93) 61.4 (8.63)
Pack-years of smoking
  Mean (SD) 47.9 (32.5) 53.9 (31.5)
DLCO
  Median (IQR) 72 (58–88) a 34.5 (26–63)
GOLD stage, No (%)
  0 255 (40.8) 15 (23.4)
  1 97 (15.5) 5 (7.8)
  2 215 (34.5) 4 (6.3)
  3 49 (7.9) 7 (10.9)
  4 8 (1.3) 33 (51.6)
an = 563 for analysis of DLCO only. Sex, age, pack-years, and Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stage all represent n = 624 and n = 64 for the 
malignant and benign groups, respectively.
SD, standard deviation; IQR, interquartile ranges.
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malignant nodule cohort. This is likely a result of the approach 
for recruitment into the LTRC database. Those subjects who 
were enrolled for a concern of lung malignancy and preceded 
to lung resection for removal of a presumptive malignant nod-
ule were more likely to have less severe emphysema. And if 
the nodule was indeed found to be histopathologically malig-
nant after resection, these were the subjects who were catego-
rized into our malignant nodule cohort. This is because those 
individuals with less severe degrees of emphysema would 
more likely have been the ones to qualify as surgical candi-
dates, and in fact, severe emphysema would have precluded 
individuals from being surgical candidates. In addition, in the 
LTRC study, only patients with severe emphysema would be 
considered for LVRS or lung transplant and may have had inci-
dentally benign nodules found on surgical resection, therefore, 
ultimately being categorized into our benign nodule cohort.
TABLE 3.  Benign Nodule Cohort
Odds Ratio (95% CI) p Value
Emphysema score severity 1.118 (0.725–1.725) 0.6137
Side: right n = 37 vs.  
left n = 27
1.339 (0.814–2.203) 0.2502
Lobe: upper n = 36 vs.  
lower n = 21
0.636 (0.331–1.222) 0.1745
Lobe: upper n = 36 vs.  
middle n = 7
0.214 (0.089–0.517) 0.006
Region: peripheral n = 53 vs.  
central n = 11
4.858 (2.536–9.309) <0.001
FIGURE 3.  Frequency of Regional 
Emphysema Scores by anatomical 
regions, nodule versus control regions in 
the benign nodule cohort. The distribu-
tion of regional emphysema of lung 
regions containing a benign nodule com-
pared with those regions that do not. 
The most frequent regional emphysema 
score in both nodule and non-nodule 
containing regions were 0. The distribu-
tion of severity of emphysema was more 
diverse in the benign cohort as com-
pared with the malignant cohort (Fig. 2).
trohoceludonngineB
NETT RES Region 
with 
nodule, 
cases 
Regions 
without nodule, 
controls 
Total 
0, No (%) 19 (29.7) 213 (30.5) 232 (30.5) 
1, No (%) 7 (10.9) 92 (13.2) 99 (13.0) 
2, No (%) 11 (17.2) 147 (21.1) 158 (20.7) 
3, No (%) 10 (15.6) 143 (20.5) 153 (20.1) 
4, No (%) 17 (26.6) 103 (14.8) 120 (15.75) 
Total 64 (8.4) 698 (91.6) 762 
A B
FIGURE 2.  Frequency of Regional 
Emphysema Scores (RES) by anatomical 
regions, nodule versus control regions in 
the malignant nodule cohort. The distri-
bution of regional emphysema of lung 
regions containing a malignant nodule 
compared with those regions that do not. 
The most frequent regional emphysema 
score in both nodule and non-nodule con-
taining regions were 0, with every few in 
the 4 (severe emphysema) category.
trohoceludontnangilaM
NETT RES Region with 
nodule, 
cases 
Regions 
without 
nodule, 
controls 
Total 
0, No (%) 324 (52.7) 4105 (60.6) 4429 (60) 
1, No (%) 166 (27.0) 1728 (25.5) 1894 (25.6) 
2, No (%) 70 (11.4) 572 (8.4) 642 (8.7) 
3, No (%) 40 (6.5) 265 (3.9) 305 (4.1) 
4, No (%) 15 (2.4) 105 (1.6) 120 (1.62) 
Total 615 (8.3) 6775 (91.7) 7390 
A B
TABLE 2.  Malignant Nodule Cohort
Odds Ratio (95% CI) p Value
Emphysema score severity 1.342 (1.112–1.620) 0.0022
Side: right n = 369 vs.  
left n = 254
1.469 (1.250–1.726) <0.001
Lobe: upper n = 344 vs.  
lower n = 232
0.776 (0.641–0.939) 0.0093
Lobe: upper n = 344 vs.  
middle n = 47
0.160 (0.116–0.220) <0.001
Region: peripheral n = 491vs.  
central n = 132
3.716 (3.061–4.510) <0.001
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Although our study is the first to semiquantitatively 
investigate the localization of the lung cancer to the anatomic 
area of emphysema, previous studies have linked emphysema 
and lung cancer. The connection was first described in 2007 
on the basis of clinical diagnosis of emphysema (as diagnosed 
by a treating physician).21 That methodology for the diagnosis 
emphysema was less than ideal with inherent bias. The stron-
gest evidence linking emphysema and lung cancer is found in a 
series of studies that have used semiquantitative methodology 
of grading radiographic emphysema by experienced radiolo-
gists.7–9 All three studies show an increase risk in lung cancer 
with emphysema, but both Wilson et al.7 and Li et al.9 describe 
the risk in a severity dependent relationship between emphy-
sema and lung cancer, with exception of the groups with the 
most severe emphysema. This suggests that there may be a 
threshold of lung parenchymal damage beyond which there is 
no longer additional risk for cancer development because the 
tissue has been nearly entirely replaced by air space.
The connection between emphysema and lung cancer, 
however, remains controversial, as there are conflicting data 
in the literature. Two studies have failed to show that emphy-
sema is a risk factor for lung cancer.22,23 Both studies used 
a  case-control design, which used computerized quantitative 
analysis of radiographic emphysema. Both found increased 
risk for lung cancer with airflow obstruction, as is consis-
tent with previous studies, indicating that the methodologi-
cal approaches of these studies were likely sound. They did 
not, however, demonstrate an association with emphysema. 
Both were relatively small studies (lung cancer cases: n = 24 
in Kishi et al.22 and n = 64 in Maldonado et al.23), with greater 
percentage of women (Kishi et al.22 n = 58% women and 
Maldonado et al.23 n = 61%), and were based on low-dose CT 
scanning techniques. Using low-dose CT scanning, it is often 
more difficult to detect subtle emphysematous disease, partic-
ularly by quantitative methods, because those scans can have 
a great deal of noise and other imaging artifacts. The image 
noise in low-dose and thin slice CT limits  threshold-based 
emphysema quantitative measure, and thus yielding poten-
tially  false-positive or false-negative pixel counts. This pat-
tern has also been noted in a recently published meta-analysis. 
There is an increased risk of lung cancer when emphysema 
is semiquantitatively assessed but this does not persist when 
emphysema is quantitatively assessed.24 It should also be 
noted that, although the data did not reach statistical sig-
nificance, Maldonado et al.23 did show that there was a trend 
toward increased risk of lung cancer in the presence of greater 
emphysema presence until overall severe emphysema was 
present. This is essentially the same finding as described by 
both Wilson et al.7 and Li et al.9 as above.
Our study represents the first investigation into the role 
of regional emphysema and the localization of lung cancer. 
Given the unique study design of subjects acting as their 
own controls, comparing regions with malignancy to regions 
without tumors in each individual subject, we were able to 
eliminate the bias and confounders that regularly accom-
pany case-control studies. However, we were unfortunately 
not able to evaluate the distribution of regional emphysema 
in subjects without pulmonary nodules; as such, individuals 
were not routinely enrolled in the LTRC database. Instead, we 
chose to look at those who had developed a benign nodule. 
Unfortunately, this group was much smaller (n = 64) than the 
malignant nodule cohort group, which limits our interpreta-
tion. This group may have been underpowered to adequately 
detect correlation of lung nodule location with regional 
emphysema scoring.
We further have no means to account for missing data 
in the LTRC database. For instance, we cannot rule out the 
possibility of bias in the calculation of the summary statistic 
of the DLCO within the malignant nodule cohort. Only 563 
data points were available for specifically the DLCO analysis. 
Those with greater obstructive disease may have had difficulty 
performing the maneuver and therefore these values would be 
missing within the database. A final limitation to the study was 
the review of the CT imaging in a semiquantitative manner. 
The regional emphysema scores were scored by experienced 
chest radiologists involved with the LTRC, but these remain 
subjective estimates and could potentially have been biased by 
the presumed presence of malignancy in the image data.
Despite these limitations, this study furthers our under-
standing of the role that emphysema may play in the develop-
ment of lung cancer. By gaining a better understanding of the 
clinical phenotype of those with COPD who develop lung can-
cer, further work can be done to better understand the mecha-
nism at a cellular level. There are presently several theories 
regarding how these two diseases are linked at the pathogenic 
level.25 The first relates to the potential role of neutrophil elas-
tase. Neutrophil elastase (NE) is a neutrophil-derived prote-
ase capable of degrading elastin. α1-antitrypsin is a naturally 
occurring antiprotease that binds and neutralizes NE. When 
NE is allowed to act unopposed, such as in the setting of clini-
cal α1-antitrypsin deficiency, emphysema results. Those with 
α1-antitrypsin have also been shown to be at increased risk 
of lung cancer as well.26 Another theory revolves around the 
activity of a family of enzymes termed matrix metalloprotein-
ases (MMPs). These enzymes are responsible for the degrada-
tion of collagen and other proteins that make up the cellular 
matrix. Two members of the family in particular, MMP1 and 
MMP9, have been not only implicated in alveolar destruction 
leading to emphysema but also in promoting tumor growth, 
leading to metastasis and invasiveness. Neutrophils and mac-
rophages have been shown to release increased amounts of 
MMPs as a result of increased levels of cytokines such as 
tumor necrosis factor-α and IL-1β resulting from activation 
of the nuclear factor-κB pathway.10,25 Tumor necrosis factor-α 
and IL-1β are well-known be upregulated in the sputum of 
patients with COPD.10 It is possible this inflammatory milieu 
could further support carcinogenesis.
In conclusion, this study demonstrates that a higher 
regional emphysema score, as a marker of emphysema sever-
ity, is associated with the presence of a malignant nodule. A 
number of questions remain regarding the role of regional 
emphysema and the development of lung cancer, and these 
questions require further study. Analysis of radiographic 
emphysema using quantitative methods has yet to conclu-
sively link emphysema and lung cancer, but certainly deserves 
additional study.
645Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 5, May 2014 Regional Emphysema and Lung Cancer
ACKNOWLEDGMENTS
The authors thank Dr. Thomas Croxton, NHLBI, for his 
inception and support of the Lung Tissue Research Consortium 
and for his suggestion to apply this analysis across the entire 
Lung Tissue Research Consortium database. The authors fur-
ther thank Dr. Antonello Punturieri, NHLBI, for his support of 
program in lung cancer and COPD.
REFERENCES
 1. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
 2. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality 
with low-dose computed tomographic screening. New Eng J Med 2011; 
365:395–409.
 3. Deaths from chronic obstructive pulmonary disease—United States, 
2000–2005. Morb Mortal Wkly Rep 2008; 57:1229–1232.
 4. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic 
obstructive pulmonary disease. A prospective, matched, controlled study. 
Ann Intern Med 1986;105:503–507.
 5. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruc-
tion and the risk for lung cancer. Ann Intern Med 1987;106:512–518.
 6. Müller NL, Coxson H. Chronic obstructive pulmonary disease. 4: imag-
ing the lungs in patients with chronic obstructive pulmonary disease. 
Thorax 2002;57:982–985.
 7. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic 
emphysema and airflow obstruction with lung cancer. Am J Respir Crit 
Care Med 2008;178:738–744.
 8. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship 
between lung cancer risk and emphysema detected on low-dose CT of the 
chest. Chest 2007;132:1932–1938.
 9. Li Y, Swensen SJ, Karabekmez LG, et al. Effect of emphysema on lung 
cancer risk in smokers: a computed tomography-based assessment. 
Cancer Prev Res (Phila) 2011;4:43–50.
 10. Barnes PJ. The cytokine network in chronic obstructive pulmonary dis-
ease. Am J Respir Cell Mol Biol 2009;41:631–638.
 11. Berry CE, Drummond MB, Han MK, et al. Relationship between lung 
function impairment and health-related quality of life in COPD and inter-
stitial lung disease. Chest 2012;142:704–711.
 12. Zhang J, Bruesewitz MR, Bartholmai BJ, McCollough CH. Selection of 
appropriate computed tomographic image reconstruction algorithms for 
a quantitative multicenter trial of diffuse lung disease. J Comput Assist 
Tomogr 2008;32:233–237.
 13. Fishman A, Martinez F, Naunheim K, et al.; National Emphysema 
Treatment Trial Research Group. A randomized trial comparing 
 lung-volume-reduction surgery with medical therapy for severe emphy-
sema. N Engl J Med 2003;348:2059–2073.
 14. American Thoracic Society. Standardization of Spirometry, 1994 Update. 
Am J Respir Crit Care Med 1995;152:1107–1136
 15. American Thoracic Society. Lung function testing: selection of ref-
erence values and interpretative strategies. Am Rev Respiratory Dis 
1991;144:1202–1218.
 16. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values 
from a sample of the general U.S. population. Am J Respir Crit Care Med 
1999;159:179–187.
 17. American Thoracic Society. Single-breath carbon monoxide dif-
fusing capacity (transfer factor). Recommendations for a standard 
technique—1995 update. Am J Respir Crit Care Med 1995;152: 
2185–2198.
 18. Crapo RO, Morris AH. Standardized single breath normal values for 
carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123: 
185–189.
 19. Rabe KF, Hurd S, Anzueto A, et al.; Global Initiative for Chronic 
Obstructive Lung Disease. Global strategy for the diagnosis, manage-
ment, and prevention of chronic obstructive pulmonary disease: GOLD 
executive summary. Am J Respir Crit Care Med 2007;176:532–555.
 20. Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. 
Cancer 1991;68:1973–1977.
 21. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstruc-
tive pulmonary disease is associated with lung cancer mortality in 
a prospective study of never smokers. Am J Respir Crit Care Med 
2007;176:285–290.
 22. Kishi K, Gurney JW, Schroeder DR, Scanlon PD, Swensen SJ, Jett JR. The 
correlation of emphysema or airway obstruction with the risk of lung can-
cer: a matched case-controlled study. Eur Respir J 2002;19:1093–1098.
 23. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett 
JR. Are airflow obstruction and radiographic evidence of emphysema risk 
factors for lung cancer? A nested case-control study using quantitative 
emphysema analysis. Chest 2010;138:1295–1302.
 24. Smith BM, Pinto L, Ezer N, Sverzellati N, Muro S, Schwartzman K. 
Emphysema detected on computed tomography and risk of lung cancer: a 
systematic review and meta-analysis. Lung Cancer 2012;77:58–63.
 25. Houghton AM. Mechanistic links between COPD and lung cancer. 
Nat Rev Cancer 2013;13:233–245.
 26. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, 
tobacco smoke, chronic obstructive pulmonary disease, and lung cancer 
risk. Arch Intern Med 2008;168:1097–1103.
